Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Protagonist Therapeutics Inc’s stock clocked out at $57.65, down -3.53% from its previous closing price of $59.76. In other words, the price has decreased by -$3.53 from its previous closing price. On the day, 2.25 million shares were traded. PTGX stock price reached its highest trading level at $60.57 during the session, while it also had its lowest trading level at $56.67.
Ratios:
To gain a deeper understanding of PTGX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.45 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.36. For the most recent quarter (mrq), Quick Ratio is recorded 12.48 and its Current Ratio is at 12.48. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on December 06, 2024, initiated with a Neutral rating and assigned the stock a target price of $47.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $62.
On November 05, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $58.Wedbush initiated its Outperform rating on November 05, 2024, with a $58 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 12 ’25 when Ali Asif bought 24,903 shares for $58.73 per share.
PATEL DINESH V PH D sold 5,359 shares of PTGX for $204,607 on Feb 19 ’25. The President and CEO now owns 540,260 shares after completing the transaction at $38.18 per share. On Nov 27 ’24, another insider, MOLINA ARTURO MD, who serves as the Chief Medical Officer of the company, sold 26,000 shares for $44.70 each. As a result, the insider received 1,162,280 and left with 46,444 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 3538804992 and an Enterprise Value of 3130757376. As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.71. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.15 while its Price-to-Book (P/B) ratio in mrq is 5.21. Its current Enterprise Value per Revenue stands at 7.207 whereas that against EBITDA is 12.342.
Stock Price History:
The Beta on a monthly basis for PTGX is 2.10, which has changed by 1.0335097 over the last 52 weeks, in comparison to a change of 0.087141395 over the same period for the S&P500. Over the past 52 weeks, PTGX has reached a high of $60.14, while it has fallen to a 52-week low of $24.22. The 50-Day Moving Average of the stock is 47.58%, while the 200-Day Moving Average is calculated to be 43.96%.
Shares Statistics:
It appears that PTGX traded 834.00K shares on average per day over the past three months and 1997780 shares per day over the past ten days. A total of 61.04M shares are outstanding, with a floating share count of 57.77M. Insiders hold about 5.89% of the company’s shares, while institutions hold 100.46% stake in the company. Shares short for PTGX as of 1740700800 were 4865114 with a Short Ratio of 5.83, compared to 1738281600 on 3793117. Therefore, it implies a Short% of Shares Outstanding of 4865114 and a Short% of Float of 8.0299996.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
